Updated from 6:56 a.m.
NEW YORK (TheStreet) -- Here are 10 things you should know for Thursday, June 18:
1. -- U.S. stock futures are rising after the Federal Reserve held off on raising interest rates until later this year, and as investors ready for Fitbit's (FIT) first day of public trading.
European stocks fell again as Greece's unresolved debt problems weighed on markets. Continental stocks are particularly hard-hit, with the Paris's CAC 40 and Frankfurt's DAX both down more than 1%. The Athens Stock Exchange fell more than 4%.
Asian stocks sank over worries about the U.S. Federal Reserve raising rates this year. Tokyo's Nikkei 225 fell more than 1%, and China's Shanghai Composite dropped 3.7%.
2. -- The economic calendar in the U.S. on Thursday includes the consumer price index at 8:30 a.m., initial jobless claims at 8:30 a.m., the Philadelphia Fed Business Outlook Survey at 10 a.m., and the Commerce Department's leading indicators at 10 a.m.
3. -- U.S. stocks on Wednesday rose slightly after the Federal Reserve Open Market Committee statement suggested that the Fed may raise interest rates before the end of the year.
4. -- The Federal Reserve did not raise interest rates this month, it announced in its Federal Open Market Committee statement on Wednesday. Yet the Fed looks at though it may raise rates before the year is over. The market's subdued but positive performance Wednesday suggests that the bump upward in rates is at least somewhat priced in to the market, as investors have had plenty of time to prepare for the change. The Fed hasn't raised rates since 2006, and the zero interest rate policy has been in place since 2008.
The Fed's dot-point graph showed that members expect two quarter-point rate raises to come in 2015 and further slowly introduced rate increases in 2016 and 2017.
The Fed also raised its estimates for 2016 gross domestic product growth to between 2.4% and 2.7%, up from 2.3% to 2.7% GDP growth estimates in March. That shows an increasing faith in economic growth at the Fed.
5. -- Fitbit begins trading for the first time Thursday on the New York Stock Exchange. The fitness watchmaker's initial public offering has priced the shares at $20 each, above the top end of the range the company initially suggested. That values the eight-year-old company at about $4.1 billion.
Fitbit will trade under the ticker FIT.
6. -- The Department of Labor announced that only 267,000 new initial jobless claims were made last week. Economists at Econoday had predicted that 275,000 new unemployment claims were made last week, down from the prior week's count of 279,000.
Jobless claims have fallen to historically low levels, suggesting a strong labor market. Low unemployment is a major factor in the Federal Reserve's decision of when to raise rates.
7. -- Cisco Systems (CSCO) will spend $10 billion in China to reclaim ground lost to Huawei Technologies and other competitors. Cisco is looking to shore up its networking business, which has been hurt by China's emphasis on homegrown technology.
Cisco will work with China's National Development and Reform Commission and focus on "innovation, equity investment, R&D and job creation," Cisco said in a statement. It also will partner with China's Association of Universities (Colleges) of Applied Science to give tech training. The investment will be made over several years, Cisco said.
In premarket trading, Cisco shares were down by 0.31%.
8. -- Crude oil prices are rising, as Brent crude oil neared $65 a barrel and West Texas Intermediate crude oil was back above $60 a barrel. Those prices reflect a better-than-1% rise as the U.S. dollar weakened after the Fed declined to raise rates.
The U.S. Energy Information Administration reported that U.S. crude oil stockpiles fell for the seventh straight week, which suggests that drillers have reduced production and that prices may have stabilized.
9. -- Synergy Pharmaceuticals (SGYP) rose 67.7% Thursday on news that its study for the experimental constipation drug plecanatide reduced chronic constipation compared to a placebo. The successful study is being followed up by a second study due to report in the third quarter. If that study is positive too, Synergy will seek FDA approval for the drug by the end of the year.
The study results have also prompted buyout speculation on Synergy.
Synergy Pharma stock is up another 6% in premarket trading Thursday.